Abstract

Cdk5 is an atypical cyclin-dependent kinase that is well characterized for its role in the central nervous system rather than in the cell cycle. However, Cdk5 has been recently implicated in the development and progression of a variety of cancers including breast, lung, colon, pancreatic, melanoma, thyroid, and brain tumors. This broad protumorigenic role makes Cdk5 a promising drug target for the development of new cancer therapies. In this review, we discuss the contribution of Cdk5 to molecular mechanisms that confer upon tumors the ability to grow, proliferate, and disseminate to secondary organs, as well as resistance to chemotherapies. We subsequently discuss existing and new strategies for targeting Cdk5 and its downstream mechanisms as anticancer treatments.

Original languageEnglish (US)
Pages (from-to)606-618
Number of pages13
JournalTrends in Cancer
Volume2
Issue number10
DOIs
StatePublished - Oct 1 2016

Fingerprint

Cyclin-Dependent Kinases
Brain Neoplasms
Melanoma
Neoplasms
Cell Cycle
Thyroid Gland
Colon
Central Nervous System
Breast Neoplasms
Drug Therapy
Lung
Therapeutics
Pharmaceutical Preparations

Keywords

  • cancer
  • Cdk5
  • resistance

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

The Emerging Role of Cdk5 in Cancer. / Pozo, Karine; Bibb, James A.

In: Trends in Cancer, Vol. 2, No. 10, 01.10.2016, p. 606-618.

Research output: Contribution to journalReview article

@article{3238c64024cc4b159bf0c0b9f2244369,
title = "The Emerging Role of Cdk5 in Cancer",
abstract = "Cdk5 is an atypical cyclin-dependent kinase that is well characterized for its role in the central nervous system rather than in the cell cycle. However, Cdk5 has been recently implicated in the development and progression of a variety of cancers including breast, lung, colon, pancreatic, melanoma, thyroid, and brain tumors. This broad protumorigenic role makes Cdk5 a promising drug target for the development of new cancer therapies. In this review, we discuss the contribution of Cdk5 to molecular mechanisms that confer upon tumors the ability to grow, proliferate, and disseminate to secondary organs, as well as resistance to chemotherapies. We subsequently discuss existing and new strategies for targeting Cdk5 and its downstream mechanisms as anticancer treatments.",
keywords = "cancer, Cdk5, resistance",
author = "Karine Pozo and Bibb, {James A.}",
year = "2016",
month = "10",
day = "1",
doi = "10.1016/j.trecan.2016.09.001",
language = "English (US)",
volume = "2",
pages = "606--618",
journal = "Trends in Cancer",
issn = "2405-8033",
publisher = "Cell Press",
number = "10",

}

TY - JOUR

T1 - The Emerging Role of Cdk5 in Cancer

AU - Pozo, Karine

AU - Bibb, James A.

PY - 2016/10/1

Y1 - 2016/10/1

N2 - Cdk5 is an atypical cyclin-dependent kinase that is well characterized for its role in the central nervous system rather than in the cell cycle. However, Cdk5 has been recently implicated in the development and progression of a variety of cancers including breast, lung, colon, pancreatic, melanoma, thyroid, and brain tumors. This broad protumorigenic role makes Cdk5 a promising drug target for the development of new cancer therapies. In this review, we discuss the contribution of Cdk5 to molecular mechanisms that confer upon tumors the ability to grow, proliferate, and disseminate to secondary organs, as well as resistance to chemotherapies. We subsequently discuss existing and new strategies for targeting Cdk5 and its downstream mechanisms as anticancer treatments.

AB - Cdk5 is an atypical cyclin-dependent kinase that is well characterized for its role in the central nervous system rather than in the cell cycle. However, Cdk5 has been recently implicated in the development and progression of a variety of cancers including breast, lung, colon, pancreatic, melanoma, thyroid, and brain tumors. This broad protumorigenic role makes Cdk5 a promising drug target for the development of new cancer therapies. In this review, we discuss the contribution of Cdk5 to molecular mechanisms that confer upon tumors the ability to grow, proliferate, and disseminate to secondary organs, as well as resistance to chemotherapies. We subsequently discuss existing and new strategies for targeting Cdk5 and its downstream mechanisms as anticancer treatments.

KW - cancer

KW - Cdk5

KW - resistance

UR - http://www.scopus.com/inward/record.url?scp=84994102504&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84994102504&partnerID=8YFLogxK

U2 - 10.1016/j.trecan.2016.09.001

DO - 10.1016/j.trecan.2016.09.001

M3 - Review article

C2 - 27917404

AN - SCOPUS:84994102504

VL - 2

SP - 606

EP - 618

JO - Trends in Cancer

JF - Trends in Cancer

SN - 2405-8033

IS - 10

ER -